Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Assets (2022 - 2025)

Fennec Pharmaceuticals' Other Non-Current Assets history spans 4 years, with the latest figure at $717000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 12.77% year-over-year to $717000.0, compared with a TTM value of $717000.0 through Dec 2025, down 12.77%, and an annual FY2025 reading of $717000.0, down 12.77% over the prior year.
  • Other Non-Current Assets for Q4 2025 was $717000.0 at Fennec Pharmaceuticals, down from $743000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $1.0 million in Q1 2024, with the low at $14000.0 in Q2 2022.
  • Average Other Non-Current Assets over 4 years is $560133.3, with a median of $743000.0 recorded in 2025.
  • Year-over-year, Other Non-Current Assets surged 833.02% in 2024 and then decreased 22.35% in 2025.
  • Tracing FENC's Other Non-Current Assets over 4 years: stood at $211000.0 in 2022, then skyrocketed by 286.73% to $816000.0 in 2023, then grew by 0.74% to $822000.0 in 2024, then fell by 12.77% to $717000.0 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Other Non-Current Assets are $717000.0 (Q4 2025), $743000.0 (Q3 2025), and $768000.0 (Q2 2025).